Supplies of high-demand obesity treatments , but that doesn鈥檛 mean it's easier to get them.
Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn鈥檛 cover the drugs . Meanwhile, some big employers are adding coverage, but their commitment isn鈥檛 guaranteed.
Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many people to afford these drugs on their own. That can make the life-changing weight loss that patients seek dependent on the coverage they have and how long it lasts.
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population , and patients have to stay on the drugs to keep the weight off.
鈥淭here are a lot of people right now who want access to the medication and can鈥檛 get it,鈥� said Katherine Hempstead, a Robert Wood Johnson Foundation senior policy adviser.
Coverage varies depending on who pays the bill
Paul Mack dropped about 70 pounds after he started taking Wegovy. The Redwood City, California, resident said food noise 鈥� constant thoughts of eating 鈥� faded, and he was able to have a heart procedure.
The treatment was covered by California鈥檚 Medicaid program, Medi-Cal. Then the 50-year-old security guard got a raise. He no longer qualified for Medi-Cal and lost coverage of the drug for several months starting last summer.
He regained two pants sizes.
鈥淚 couldn鈥檛 control the eating,鈥� he said. 鈥淎ll the noise came back.鈥�
Coverage of these drugs remains patchy more than a year after Zepbound entered the market to challenge Wegovy.
The benefits consultant Mercer says 44% of U.S. companies with 500 or more employees covered obesity drugs last year. It's even more common with bigger employers.
More than a dozen government-funded Medicaid programs for people with low incomes also cover obesity treatments.
But few insurers cover the drugs on individual insurance marketplaces. And some plans restrict their coverage with things like requests for prior authorization or pre-approval.
The lack of Medicare coverage remains a concern as well, especially for people who retire and move to the government-funded program from employer-sponsored coverage.
鈥淧atients come to us terrified about switching to Medicare and losing coverage,鈥� said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and cofounder of the obesity treatment company FlyteHealth. 鈥淲e start talking about backup plans a year before they transition.鈥�
Cost and uncertain payoff loom as concerns payer concerns
Philadelphia-area insurer Independence Blue Cross dropped coverage of the drugs solely for weight loss for some customers starting this year. Company officials say the insurer worried about premium hikes it would have to impose on all customers if it continued.
Cost also was a factor in decisions by and officials to end similar programs that provided coverage for state employees.
These concerns make Vanderbilt University researcher Stacie Dusetzina wonder how long employers who have added coverage will keep it, now that the drugs are .
鈥淭hat鈥檚 probably going to spike spending,鈥� said Dusetzina, a health policy professor who studies drug costs.
Drugmakers tout the savings these drugs can provide by improving patient health and warding off future serious medical conditions like heart attacks or strokes.
But health care experts note that there are no guarantees that the employer or insurer who covers the drug will eventually reap those benefits because people may change jobs or insurers.
Will coverage ever become consistent?
There鈥檚 no clear path toward widespread coverage of these drugs for obesity, even as polls show having Medicaid and Medicare cover the costs.
Leaders at Zepbound maker Eli Lilly have seen coverage grow steadily for their drug, and they're optimistic that will continue.
Former President Joe Biden鈥檚 administration that would allow for Medicare and broader Medicaid coverage. Its fate remains uncertain in President Donald Trump鈥檚 administration.
A bill calling for Medicare coverage has been floating around Congress for years. But it isn鈥檛 scheduled for a vote.
Drugmakers are currently testing several additional obesity treatments. Such potential competition could reduce prices and prompt more coverage.
Patchy coverage complicates treatment plans
Dr. Amy Rothberg says the lack of consistent coverage leaves her conflicted about writing prescriptions because she鈥檚 not sure how long patients will be able to take the drug.
鈥淲e know from the studies that people , they regain their weight,鈥� said Rothberg, director of the University of Michigan鈥檚 weight-management program. 鈥淚 don鈥檛 want to do harm.鈥�
Some insurers require diet and exercise changes for the patient before they will cover a weight-loss medication. Those changes should happen in conjunction with starting the medicine, said Dr. Lydia Alexander, president of the Obesity Medicine Association.
She鈥檚 also seen requirements for a body mass index of 40 or more, which equates to severe obesity, before coverage can start.
鈥淲e鈥檙e saying that obesity is a disease, but we're not treating it like a disease,鈥� she said.
____ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute鈥檚 Science and Educational Media Group. The AP is solely responsible for all content.
Tom Murphy, The Associated Press
